The value of 3.0Tesla diffusion-weighted MRI for pelvic nodal staging in patients with early stage cervical cancer  by Klerkx, W.M. et al.
European Journal of Cancer (2012) 48, 3414–3421Ava i l ab l e a t www.s c i enced i r ec t . com
journa l homepage : www.e j cancer . in foThe value of 3.0 Tesla diﬀusion-weighted MRI for pelvic
nodal staging in patients with early stage cervical cancerW.M. Klerkx a,⇑, W.B. Veldhuis b, A.M. Spijkerboer c, M.A. van den Bosch b, W.P. Mali b,
A.P. Heintz a, S. Bipat c, D.M. Sie-Go d, J. van der Velden e, H.W. Schreuder a, J. Stoker c,
P.H. Peeters faDepartment of Gynecology and Obstetrics, University Medical Center Utrecht, The Netherlands
bDepartment of Radiology, University Medical Center Utrecht, The Netherlands
cDepartment of Radiology, Amsterdam Medical Center, The Netherlands
dDepartment of Pathology, University Medical Center Utrecht, The Netherlands
eDepartment of Gynecology and Obstetrics, Amsterdam Medical Center, The Netherlands
f Julius Center for Health Sciences and Primary Care, Utrecht, The NetherlandsAvailable online 24 July 201209
ht
⇑
UKEYWORDS
Cervix cancinoma
Lymph node metastasis
DWI
Diagnostic accuracy
Speciﬁcity59-8049 2012 Elsevier Ltd.
tp://dx.doi.org/10.1016/j.ejca.
Corresponding author: Addr
trecht, The Netherlands. Tel.
E-mail address: w.klerkx@u2012.06.0
ess: Dep
: +31 08
mcutrech
Open acceAbstract Objective: The purpose of this study is to investigate the diagnostic accuracy of
3.0 Tesla (3T) diffusion-weighted magnetic resonance imaging (MRI) in addition to conven-
tional MRI for the detection of lymphadenopathy in patients with early stage cervical cancer
compared to histopathological evaluation of the systematically removed pelvic lymph nodes as
reference standard.
Methods: 68 fe´de´ration internationale de gyne´cologie obste´trique (FIGO) stage Ia2 to IIb cer-
vical cancer patients were included. Sensitivity and speciﬁcity rates for two experienced
observers were computed for the detection of lymphatic metastasis. Reproducibility of con-
ventional MRI was tested by kappa statistics. The variables included in the analysis were: size
of the long axis, short axis, ratio short to long axis and apparent diffusion coefﬁcient (ADC).
Results: Nine patients had 15 positive pelvic nodes at histopathological examination. The sen-
sitivity and speciﬁcity of lymphatic metastasis detection by predeﬁned conventional MRI
characteristics was 33% (95% Conﬁdence Interval (CI) 3–64) and 83% (95% CI 74–93) on
patient level, and 33% (95% CI 7–60) and 97% (95% CI 95–99) on regional level respectively
for observer 1. For observer 2 the sensitivity was 33% (95% CI 3–64) and the speciﬁcity 93%
(95% CI 87–100) on patient level, and 25% (95% CI 1–50) and 98% (95% CI 97–100) on regio-22
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Table 1
Scan sequences.
Axia
ﬁeld
Bandwidth (Hz) 1264
Echo time (ms) 2
Repetition time (ms) 394
Flip angle () 75
TSE (turbo spin echo)/
EPI factor
Inversion delay (ms)
a Spectrally-selective adiabatic
b Spectral selection attenuate
sequence.
W.M. Klerkx et al. / European Journal of Cancer 48 (2012) 3414–3421 3415nal level, respectively. The kappa-value for reproducibility of metastasis detection on regional
level was 0.50. The short axis diameter showed the highest diagnostic accuracy (area under the
curve (AUC) = 0.81 95% CI 0.70–0.91); ADC did not improve diagnostic accuracy
(AUC = 0.83 95% CI 0.73–0.93).
Conclusions: Diffusion-weighted MRI did not result in additional diagnostic value compared
to conventional MRI.
 2012 Elsevier Ltd.Open access under the Elsevier OA license. 1. Introduction
Histopathological examination of lymph nodes is still
regarded the gold standard for establishing lymph node
involvement in early stage cervical cancer; treatment
options depend on nodal status. The method to obtain
this information is invasive and thus bears a risk of com-
plications. Furthermore, due to early detection of
tumours and the introduction of screening programs,
the number of patients with positive lymph nodes is
low: 85% turns out to be node-negative.1 The conse-
quence is that for these patients the justiﬁcation of an
invasive and expensive diagnostic method is debatable.
Lymph nodes can be evaluated by MRI using their
size and morphological aspect as malignancy character-
istics. The speciﬁcity of MRI to exclude lymph node
metastasis in early stage cervical cancer patients is high
(over 90%), facilitated by the fact that the prevalence of
lymph node metastasis in this patient group is low.1,2
The sensitivity on the other hand is limited due to the
inability to detect lymphatic metastasis in normal-sized
and -shaped nodes.2,3 Diﬀusion-weighted MRI (DWI)
has been suggested to improve the diﬀerentiation
between normal and metastatic nodes by means of dif-
ferences in signal intensity quantiﬁed as the apparent
diﬀusion coeﬃcient (ADC).4,5 Preliminary studies
showed promising results on nodal staging in cervical
cancer patients.6–8 However there is no consistent
evidence on how to interpret ADCs, both positive and
negative correlations were found between ADC and
metastasis.8,9
We conducted a prospective cohort study in early
stage cervical cancer patients about to undergo a sys-
tematic pelvic lymphadenectomy to investigate the diag-l T1 fast
echo
Axial T2 turbo
spin echo
.2
.3 80
3429
20
inversion recovery sequence.
d inversion recovery (SPAIR) fat-nostic accuracy of fat-suppressed T2-weighted MRI
scan and the added value of DWI at 3.0 T.2. Patients and methods
2.1. Patients
Eligible patients were consecutive non-pregnant
women with histopathologically conﬁrmed cervical car-
cinoma and clinically staged as FIGO (International
Federation of Gynaecology and Obstetrics) stage Ia2
to IIb. Women were over 18 years of age and scheduled
for systematic pelvic lymphadenectomy. Patients were
prospectively included in two tertiary referral clinics.
Exclusion criteria were contra-indications for MRI, i.e.
cardiac pacemaker, claustrophobia or surgical clips in
the brain. The local ethics research committees
approved the study and informed consent was obtained
from all patients. The study was registered at http://clin-
icaltrials.gov at NCT00288821.2.2. Conventional MR imaging
In both centres patients were scanned on a 3.0 T MR
scanner using a phased-array sensitivity encoding
(SENSE) torso or cardiac coil (Achieva, Philips Health-
care, Best, The Netherlands). The ﬁeld of view was set
from the pubic symphysis to the common iliac arteries.
The scan parameters are shown in Table 1. The ﬁeld
of view was 360  360 mm for all conventional
sequences, with a slice thickness of 4 mm and a 0 mm
slice gap. This slice thickness and gap were chosen to
compare DWI and conventional MRI slice by slice.Axial fat-suppressed
T2 SPAIRa
Sagittal fat-suppressed
T2 SPAIRa
DWIb
80 80 54
2881 2881 5000
41
110 110
suppressed single shot spin-echo EPI (echo planar imaging)
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tion was acquired with a matrix size of 512  512. The
slice thickness and gap for the DWI sequence were 4
and 0 mm; the matrix was 256  256. Four b-values
were used; 0, 150, 500 and 1000 s/mm2.2.3. Image analysis
2.3.1. Test phase
All images were assessed by two board certiﬁed onco-
logical radiologists of which one (observer 1) was a
fellowship-trained abdominal and oncological radiolo-
gist with 9 years of experience in gynaecologic imaging
and 15 years in body imaging in general. Observer 2
was a fellowship-trained interventional radiologist with
special interest in oncology with three years of experi-
ence. At start, a consensus meeting was organised dur-
ing which aforementioned scan sequences of patients
not included in the study were shown and evaluated to
obtain standardised test evaluations. All analyses were
done on a picture archiving and communications system
(PACS) workstation (Philips EasyVision DX).2.3.2. T2-weighted (T2W) image assessment
The observers had no knowledge of clinical character-
istics or FIGO stage. All lymph nodes with a long axis
diameter measuring more than 5 mm in axial direction
were registered. The following characteristics wereFig. 1. A) Axial T2-weighted SPAIR, fused with DWI (b = 1000 s/m2). Pa
weighted SPAIR without the fusion image. (C) Apparent diﬀusion coeﬃcie
lymph node: a manually placed region of interest (ROI). (E) The ROI is tassessed: the axial sequence and slice at which the node
was measured, the size (diameter of the long and short
axis in millimetre), the border (spiculated, lobulated,
indistinct or smooth) and the region (left and right exter-
nal iliac, obturator fossa, common iliac). The position of
a node was categorised in six anatomical regions: the
external iliac region was deﬁned as located medial and
cranial to the external iliac vein, while the obturator
region covered the caudal area of the external iliac vein
until the internal iliac vessels. The common iliac region
included lymph nodes from the bifurcation of the internal
and external iliac arteries until the bifurcation of both
common iliac arteries. These regions are similar to the
surgical margins of the removed node bearing tissue.
Based on conventional MRI sequences metastasis was
predeﬁned as: more than 10 mm in short axis diameter
or more than 8 mm in long axis diameter with a rounded
shape (deﬁned as short:long axis ratio over 0.8). Each pel-
vic region was classiﬁed as either positive or negative
based on the nodal assessment of the observers.2.3.3. Additional DWI assessment
During the review process colour fusion images of
the highest b-value diﬀusion-weighted data set and
the anatomical T2-weighted data set were used to
facilitate the detection of pelvic lymph nodes.10 The
ADC map was automatically processed with in-house
developed software using four b-values, i.e. 0, 150,ra-iliac lymph nodes are highlighted and easier to detect. (B) Axial T2-
nt (ADC) map of this slice. (D) ADC measurement of the highlighted
hen copied to the ADC map and manually adjusted if necessary.
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manually drawn by both observers on the transverse
slice on which the maximal size of the lymph node
was measured (Fig. 1). Small interspaces to the border
were kept in order to prevent partial volume eﬀect.
The ROI drawn on the fusion image was automati-
cally copied to the ADC map and manually adjusted
if necessary. The mean ADC of a lymph node was
used in the evaluation. For comparison of normalised
ADCs, a ROI was drawn in the psoas muscle and, if it
could be delineated, in the primary tumour.2.4. Surgical procedure
Surgical procedures were performed by experienced
gynaecological oncologists. A radical hysterectomy was
combined with bilateral pelvic lymph node dissection
(PLND) in all patients. The surgeons were blinded to
the number and localisation of the pelvic lymph nodes
detected by imaging. All lymph nodes were collected from
the six anatomical regions. The primary tumour and lym-83 included patients 
70 included patients 
38 Centre 1 30 Centre 2 
5 no DWI 
2 motion-d
2 image fu
weighted M
angulation
2 chemora
1 neo-adju
1 surgery i
9 patients had 15 positive pelvic 
lymph nodes in 12 pelvic regions 
2 patients 
nodes at su
section of 
systematic
performed
Fig. 2. Flowchart ofphadenectomy specimens were sent to the pathologist
separately for routine histopathologic examination.2.5. Histopathology
After routine processing and embedding in paraﬃn of
non-ﬁxated lymph nodes, they were cut in parallel sec-
tions of 2 mm thickness. The sections were stained with
Haematoxylin and Eosin and examined by a specialised
pathologist in gynaecological oncology. The pathologist
was blinded to the radiological ﬁndings. The pathologist
counted the number of lymph nodes per anatomical site
and scored the presence of metastasis per localised
lymph node. Histopathological results were used as ref-
erence standard.2.6. Image data versus histopathology
The lymph nodes detected by imaging were correlated
to the surgical removed lymph nodes based on region
and position by an independent reviewer. In some casesscan  
egraded DWI 
sion not possible because DWI an T2-
RI were acquired with different 
  
diation therapy 
vant chemo therapy after the scan 
n other hospital  
had suspicion of pathological lymph 
rgery, this was proven by frozen 
these nodes during surgery and no 
 lymph node dissection was 
. 
59 patients had negative pelvic 
lymph nodes 
included patients.
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the lymph nodes found at histopathological examination
and those found by imaging. When the pathologist
detected more lymph nodes than the radiologists
observed by imaging, we chose the largest lymph node
as the one most likely observed by imaging. For exam-
ple, if the pathologist detected four lymph nodes in the
right obturator region of which one was metastatic
and three normal and the radiologists observed fewer
nodes, the largest node measured by the observers was
considered the malignant node.Table 2
Tumour characteristics of 68 patients.
Number
(mean ± SD)
% (range)
Stage of disease
Ia2 2 2.9
Ib1 58 85.3
Ib2 4 5.9
IIa 3 4.4
IIb 1 1.5
Age at inclusion (years) 44.3 (±10.1) 22.4–75.4
Days between scan and surgery 19.3 (±10.5) 1–44
Symptoms at time of diagnosis
None, routine cytology 26 38.2
Postcoital bleeding 23 33.8
Abnormal uterine bleeding 18 26.5
Abdominal pain 1 1.5
Type of carcinoma
Squamous cell carcinoma 47 69.1
Adenocarcinoma 16 23.5
Adenosquamous cell
carcinoma
4 5.92.7. Statistical analysis
To ﬁnd an additional diagnostic value of 20% we
computed (using a = 0.05 and b = 0.2 and a sensitivity
rate of 70% instead of 50% (with 95% conﬁdence inter-
val (CI) of ±25%)) 13 patients with pelvic lymph node
metastasis would be needed.2,3 With a pelvic lymph node
metastasis rate of 15–20% approximately 74 patients
should be included.
Frequency statistics were used for descriptive analy-
sis. Normality was checked before proceeding with
testing for diﬀerences between the observers (paired
sample t-tests). If data were not normally distributed
or categorical a Wilcoxon signed ranks test was used.
We computed sensitivity and speciﬁcity values with
95% CI per region and per patient for the predeﬁned
malignancy criteria, i.e. short axis >10 mm or long axis
>8 mm and a round shape (short to long axis ratio
>0.8). Kappa statistics were calculated to express interob-
server agreement for classiﬁcation of metastasized
regions and patients. To test the added value of DWI, test
performances with diﬀerent threshold levels for all vari-
ables were computed and receiver operating characteris-
tic (ROC) curves were estimated for the more
experienced observer. The best performing variables were
combined to compute optimal diagnostic accuracy. The
new set of variables was tested withMcNemar test for sig-
niﬁcant diﬀerence with the predeﬁned malignancy
criteria.
A p-value of less than 0.05 was considered statisti-
cally signiﬁcant. Data were analysed using the Statistical
Package for the Social Sciences version 15.0 (SPSS Inc.,
Chicago, IL). Sensitivity analyses were performed when
patient characteristics were exceptional or could disturb
test results.Clear cell carcinoma 1 1.5
Diﬀerentiation grade of tumour
Good 5 7.4
Moderate 33 48.5
Poor 10 14.7
Missing 20 29.4
Smoking
Never 31 45.6
Quit 11 16.2
Actual 25 36.7
Missing 1 1.53. Results
Eighty-three patients were included from February
2006 to 2009 (Fig. 2). After exclusion of 15 patients 68
patients could be included in the analysis. Nine of these
patients had 15 positive lymph nodes in 12 pelvic regions
(Table 2). Most patients (85.3%) had stage IbI disease,
one patient had FIGO stage IIb and was included afterneo-adjuvant chemotherapy. Themean duration between
the scans and surgery was 19 days (range 1–44). Two
patients had surgery more than 6 weeks after the scan.
Observer 1 detected more lymph nodes than obser-
ver 2 in all pelvic regions (Table 3). However, still only
25.5% of nodes histologically conﬁrmed were detected
by this observer. Almost all histologically conﬁrmed
malignant nodes were detected by both radiologists
(100% for observer 1, 80% for observer 2). However
the majority of these detected lymph nodes were not
classiﬁed as such by the predeﬁned malignancy criteria
(i.e. short axis >10 mm or long axis >8 mm and a
round shape (short to long axis ratio >0.8): 4 out of
15 lymph nodes for observer 1 and 3 out of 15 lymph
nodes for observer 2. The remaining metastatic lymph
nodes were too small or too elongated to be character-
ised as metastasis. On regional level the sensitivity of
lymphatic metastasis detection was 33.3% (95% CI
6.7–60.0) with a speciﬁcity of 96.7% (95% CI 94.9–
98.5) for observer 1 and 25.0% (95% CI 0.5–49.5)
and 98.2% (95% CI 96.9–99.5), respectively for obser-
ver 2. The interobserver agreement was 0.50 on regio-
nal level and 0.42 on patient level.
When analysing the diﬀerence in malignancy charac-
teristics between normal and metastatic nodes the
following results were seen: short and long axis diame-
ters are both signiﬁcantly larger in metastatic nodes
Table 3
Characteristics of conventional MRI, diﬀusion weighted MRI and histology.
Observer 1 N (% of histopathological
counted nodes)
Observer 2 N (% of histopathological
counted nodes)
Histology
Number of nodes
Obturator
region
280 (35.3%) 95 (12.0%) 793 (100%)
External iliac
region
97 (13.7%) 116 (16.4%) 707 (100%)
Common iliac
region
78 (40.6%) 22 (11.5%) 192 (100%)
Total 455 (25.5%) 233 (13.0%) 1786a (100%)
Metastasis 18 lymph nodes in 17 regions in 13
patients (1–3 per patient)
10 lymph nodes in 10 regions in 7
patients (1–2 per patient)
15 lymph nodes in 12 regions in 9
patients (1–3 per patient)
Median (interquartile range) Mean (±SD) Median (interquartile range) Mean
(±SD)
p
Short axis
diameter(mm)
4.8 (4.0–5.9) 5.0 (4.0–5.9) 0.00b
Long axis
diameter(mm)
9.7 (7.3–12.4) 11.0 (8.6–13.7) 0.79b
Ratio short:long
axis
0.54 (0.40–0.69) 0.47 (0.34–0.64) 0.00b
Border
Smooth 327 (71.9%) 188 (80.7%)
Spiculated 7 (1.5%) 0 (0%)
Lobulated 112 (24.6%) 26 (11.2%)
Indistinct 9 (2.0%) 19 (8.2%)
a In three patients the number of lymph nodes detected at histopathological examination was not recorded per anatomic region.
b Wilcoxon signed ranks test.
Fig. 3. Receiver operating characteristic (ROC) curves of morphological characteristics on conventional MRI. AUC short axis diameter with 95%
Conﬁdence Interval (CI): 0.81 (0.70–0.91). AUC long axis diameter with 95% CI: 0.69 (0.54–0.84). AUC ratio short:long axis diameter with 95%
CI: 0.67 (0.54–0.79). AUC apparent diﬀusion coeﬃcient (ADC) with 95% CI: 0.62 (0.48–0.76).
W.M. Klerkx et al. / European Journal of Cancer 48 (2012) 3414–3421 3419(5.1 mm versus 8.2 mm, p = 0.00 and 10.2 mm versus
12.6 mm, p = 0.04 respectively for observer 1 and
5.2 mm versus 7.9 mm, p = 0.00 and 11.1 mm versus
14.3 mm, p = 0.03 for observer 2). The ADC was not
signiﬁcantly diﬀerent in metastatic nodes (0.62  103
versus 0.67  103 mm2/s, p = 0.06 for observer 1 and0.64  103 versus 0.72  103 mm2/s, p = 0.06 for
observer 2 respectively).
The criterion ‘short axis diameter’ had the best AUC
(0.81 95% CI 0.70–0.91, Fig. 3). Adding ADC as
variable only slightly improved the AUC (0.83 95% CI
0.73–0.93). The sensitivity and speciﬁcity of short axis
Table 4
Diagnostic accuracy at diﬀerent cut-oﬀ values for all malignancy
criteria per pelvic region.
Characteristic AUC (95% Conﬁdence Interval (CI)) Sens Spec
Long axis 0.69 (0.54–0.84)
>8 mm 0.80 0.32
>10 mm 0.73 0.54
>12 mm 0.53 0.82
>14 mm 0.40 0.87
>16 mm 0.20 0.94
Short Axis 0.81 (0.70–0.91)
>5 mm 0.80 0.57
>6 mm 0.67 0.79
>7 mm 0.47 0.89
>8 mm 0.47 0.95
>9 mm 0.33 0.98
>10 mm 0.27 0.99
Ratio 0.67 (0.54–0.79)
>0.5 0.80 0.45
>0.6 0.53 0.73
>0.7 0.47 0.77
>0.8 0.27 0.89
>0.9 0.07 0.96
ADC 0.62 (0.48–0.76)
<0.00080 0.93 0.27
<0.00070 0.71 0.51
<0.00065 0.36 0.74
<0.00060 0.36 0.76
<0.00055 0.29 0.85
<0.00050 0.29 0.93
Border
Lobulated 0.51 (0.36–0.66) 0.27 0.75
Spiculated 0.49 (0.35–0.64) 0.00 0.98
Indistinct 0.49 (0.34–0.64) 0.00 0.98
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eral cut-oﬀ values. Best sensitivity and speciﬁcity rates
are acquired by combined short axis diameter >8 mm
with an ADC < 0.80  103 mm2/s, resulting in a sensi-
tivity of 42.9 (95% CI 16.9–68.8) (p = 0.63 compared to
SA > 8 mm alone) and speciﬁcity 96.6 (95% CI 94.8–
98.3) (p = 1.0 respectively). Characterising the border
of a lymph node had the worst test performance
(AUC = 0.49–0.51) (Table 4).
We performed sensitivity analyses – by excluding the
case with IIB disease and the patients with >6 weeks
between scan and surgery – however this did not change
the results.4. Discussion
There is a growing awareness of the limited diagnos-
tic accuracy of morphologic imaging criteria for staging
lymph nodes even at high and ultra-high ﬁeld
strengths.11 The ADC of lymph nodes is low, so both
benign and metastatic lymph nodes are bright on high
b-value diﬀusion-weighted images. This facilitates their
recognition and discrimination from vessels and other
pelvic structures.4,5 Using ADC as imaging biomarker
is attractive because it is non-invasive, does not requireexogenous contrast agents or ionising radiation and is
easily incorporated into routine MRI protocols.
A series of patients (n = 25) with cervical cancer was
preoperatively scanned on a 3 T MR scanner by Yu
et al.12 In this study the ADCs of 17 metastatic pelvic
lymph nodes found at histopathological evaluation were
compared to the ADCs of 140 benign nodes. A statisti-
cal signiﬁcant diﬀerence in ADC was found between
normal and metastatic nodes (0.86 ± 0.36  103 versus
1.12 ± 0.34  103 mm2/s, p = 0.004). The diagnostic
performance of DWI was not evaluated in this study.
The ADC threshold for discriminating metastatic
from benign nodes in cervical cancer patients varied lar-
gely studies: 0.712  103–1.15  103 mm2/s.6,8 Alter-
natives were sought, such as using the relative ADC
(dividing or subtracting lymph node ADC by tumour
ADC), to assess the nodal status with conﬂicting
results.6,8,13 In our analysis (data not shown) relative
ADC between tumour and lymph node or muscle and
lymph node was not signiﬁcantly diﬀerent in metastatic
and normal lymph nodes.
An important alternative competing with functional
imaging in cervical cancer staging is the sentinel lymph
node biopsy (SNB) in cervical cancer patients. Recently
a multi-centre study involving 145 cervical cancer
patients showed a sensitivity of 92% and a negative pre-
dictive value of 98.2%.14 There were no false-negative
results in 76.5% of the patients in whom the sentinel
lymph nodes were detected bilaterally. It must be
noticed that all sentinel nodes were evaluated by ultra-
staging; a time-consuming method which cannot be per-
formed during surgery. Since the start of our study some
clinics started to use SNB staging in early stage cervical
cancer patients. However, to date a complete pelvic lym-
phadenectomy without SNB in early-stage cervical can-
cer is still advised by international guidelines.15,16
A few limitations of our study should be considered.
First, a node-by-node analysis could not be performed
because it was not feasible to remove and evaluate node
bearing tissue in the exact anatomic position in which it
is found in the pelvis. Comparison on regional level was
considered the best possible estimate we could provide.
Also, by mismatching of the number of nodes identiﬁed
by radiologist and pathologist we decided to match the
largest node (measure by radiologist) to be the malig-
nant one. This approach could introduce bias, however
by performing a region-by-region comparison results
presented are less susceptible to bias. Blinding of the
observers to clinical parameters such as age, tumour
type and clinical stage is not according to clinical prac-
tice, but in an experimental setting it is the best way to
avoid bias. Finally, we included a relatively small num-
ber of women with only a few positive lymph nodes.
Although cervical cancer is the third most common can-
cer in women with worldwide 530,000 new cases each
year,17 85% of these patients present in developing coun-
W.M. Klerkx et al. / European Journal of Cancer 48 (2012) 3414–3421 3421tries with limited resources. It is clear that multi-centre
and likely also multinational prospective studies are
needed to improve care in cervical cancer patients.
In conclusion, the results of this prospective, dual-
centre clinical study demonstrate that the sensitivity of
conventional MRI to detect metastatic pelvic lymph
nodes in cervical cancer patients is modest. ADC does
not improve the diagnostic performance of the best dis-
criminator, short axis diameter, to distinguish malignant
from non-malignant pelvic lymph nodes in early stage
cervical cancer patients. The clinical relevance of ADC
to detect lymphatic metastasis is currently low.
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